From: Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer
 | Ovarian cancer | Controls | ||
---|---|---|---|---|
Adenocarcinoma papillare serosum | Adenocarcinoma mucinosum | Adenocarcinoma endometrioides | n = 80 | |
n = 82 | n = 44 | n = 23 | ||
Anti-Hsp60 (AU/ml) | 104,17 ± 159,89 | 82,94 ± 82,87 | 77,77 ± 83,41 | 62,42 ± 33,93 |
(mean ± SD) | ||||
  % of positive results | 26%* | 19% | 21% | 10% |
  (> 90 percentile for control group) | p = 0.0075 | p = 0.1476 | p = 0.1535 | |
Anti-Hsp65 (AU/ml) | 106,41 ± 217,07 | 78,64 ± 85,73 | 85,32 ± 92,47 | 56,35 ± 35,57 |
(mean ± SD) | ||||
  % of positive results | 21,5%* | 15% | 29%* | 10% |
  (> 90 percentile for control group) | p = 0.0424 | p = 0.3972 | p = 0.0200 |